Sixty percent of liver cancers are preventable by controlling risk factors including hepatitis B and C, alcohol consumption, ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

During Brazil's COVID-19 vaccination campaign, when several brands of vaccines were available and the Chinese vaccine was the ...

Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results ...

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

AIM ImmunoTech shares climbed after the company reported positive data from a Phase 2 study evaluating treatment of metastatic pancreatic cancer patients with stable disease after a combination ...

Shares of AstraZeneca were trading at $72.66 as of July 25. Over the last 52-week period, shares are down 7.46%. Given that these returns are generally negative, long-term shareholders are likely ...

New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Data analytics software company Palantir (PLTR) closed at a fresh high of $158.80 (£118.32) per share on Friday and rose another 1% in pre-market trading on Monday. Shares climbed after Piper Sandler ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...